AJDRAJNR - American Journal of Neuroradiology

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bezabeh, T.
Right arrow Articles by Smith, I. C.P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bezabeh, T.
Right arrow Articles by Smith, I. C.P.

Prediction of Treatment Response in Head and Neck Cancer by Magnetic Resonance Spectroscopy

Tedros Bezabeha, Olva Odluma,b, Richard Nasona,c, Paul Kerra,c, Donna Sutherlanda,c, Rakesh Patela and Ian C.P. Smitha

a From the Institute for Biodiagnostics, National Research Council, University of Manitoba, Canada
b Faculty of Dentistry, University of Manitoba, Canada
c CancerCare Manitoba, Winnipeg, Manitoba, Canada



View larger version (18K):

[in a new window]
 
FIG 1. 360 MHz 1H MR spectra of head and neck tumors (A) control (B) failed case. Both specimens came from oral tongue tumors. Chos, choline-containing compounds; Cr, creatines; Gln, glutamine; Glu, glutamic acid; HOD, deuteriated water; Lac, lactic acid; Leu, leucine; Lip, lipid; Tau, taurine; Val, valine. Assignments do not imply that these are the only substances contributing to a particular peak.



View larger version (11K):

[in a new window]
 
FIG 2. Bar graphs of the 3.2/3.0 spectral intensity ratio (mean ± SEM). Dark shade, control; light shade, failed cases; A, tumors from all sites included; B, tumors of the tongue only.



View larger version (11K):

[in a new window]
 
FIG 3. Bar graphs of the 1.3/0.9 spectral intensity ratio (mean ± SEM). Dark shade, control; light shade, failed cases; A, tumors from all sites included; B, tumors of the larynx only.